CA2871111C - Epitopes of epidermal growth factor receptor surface antigen and use thereof - Google Patents

Epitopes of epidermal growth factor receptor surface antigen and use thereof Download PDF

Info

Publication number
CA2871111C
CA2871111C CA2871111A CA2871111A CA2871111C CA 2871111 C CA2871111 C CA 2871111C CA 2871111 A CA2871111 A CA 2871111A CA 2871111 A CA2871111 A CA 2871111A CA 2871111 C CA2871111 C CA 2871111C
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
seq
egfr
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2871111A
Other languages
English (en)
French (fr)
Other versions
CA2871111A1 (en
Inventor
Se-Ho Kim
Kwang-Won Hong
Ki Hwan Chang
Min-Soo Kim
Mi-Jung Lee
Jong-Hwa Won
Min-Kyu Hur
Hyun-Soo Cho
Ji-Ho YOO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Biotechnology Research Institute
GC Biopharma Corp
Original Assignee
Green Cross Corp Korea
Mogam Biotechnology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Korea, Mogam Biotechnology Research Institute filed Critical Green Cross Corp Korea
Publication of CA2871111A1 publication Critical patent/CA2871111A1/en
Application granted granted Critical
Publication of CA2871111C publication Critical patent/CA2871111C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
CA2871111A 2012-03-27 2013-03-27 Epitopes of epidermal growth factor receptor surface antigen and use thereof Active CA2871111C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616073P 2012-03-27 2012-03-27
US61/616,073 2012-03-27
PCT/KR2013/002550 WO2013147509A1 (ko) 2012-03-27 2013-03-27 표피 성장 인자 수용체 표면 항원상의 에피토프 및 이의 용도

Publications (2)

Publication Number Publication Date
CA2871111A1 CA2871111A1 (en) 2013-10-03
CA2871111C true CA2871111C (en) 2022-06-28

Family

ID=49260689

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871111A Active CA2871111C (en) 2012-03-27 2013-03-27 Epitopes of epidermal growth factor receptor surface antigen and use thereof

Country Status (16)

Country Link
US (3) US20150231220A1 (enExample)
EP (1) EP2832363B1 (enExample)
JP (1) JP6209206B2 (enExample)
KR (1) KR101930019B1 (enExample)
CN (2) CN104394879A (enExample)
BR (1) BR112014024192A2 (enExample)
CA (1) CA2871111C (enExample)
CO (1) CO7160042A2 (enExample)
DK (1) DK2832363T3 (enExample)
ES (1) ES2694679T3 (enExample)
IN (1) IN2014DN08778A (enExample)
MX (1) MX356550B (enExample)
MY (1) MY168077A (enExample)
PH (1) PH12014502360A1 (enExample)
RU (1) RU2650770C2 (enExample)
WO (1) WO2013147509A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011386A1 (en) * 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
CN115226700A (zh) * 2022-08-02 2022-10-25 江苏克诺克智能科技有限公司 一种粮面害虫诱捕器及诱捕系统

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0975748B1 (en) 1997-04-23 2006-03-29 Universität Zürich Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
US7732157B1 (en) * 1999-09-30 2010-06-08 Tumor Biology Investment Group Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods
ES2259030T3 (es) * 2000-05-19 2006-09-16 Scancell Limited Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico.
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
IL159225A0 (en) * 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
JP2003066677A (ja) * 2001-08-24 2003-03-05 Canon Inc カラー画像形成装置及び画像補正制御方法並びに記憶媒体
US7736644B2 (en) * 2003-06-27 2010-06-15 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP1871805B1 (en) * 2005-02-07 2019-09-25 Roche Glycart AG Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
WO2006102901A2 (en) * 2005-03-31 2006-10-05 Pharmexa A/S Immunogenic egfr peptides comprising foreign t cell stimulating epitope
US7985559B2 (en) * 2007-10-19 2011-07-26 Amgen Inc. Methods of selecting epidermal growth factor receptor (EGFR) binding agents
AU2009301580B2 (en) * 2008-10-06 2015-11-26 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
WO2011140391A2 (en) * 2010-05-05 2011-11-10 The Research Foundation Of State University Of New York Egfr-related polypeptides and methods of use

Also Published As

Publication number Publication date
PH12014502360B1 (en) 2015-01-12
RU2014143032A (ru) 2016-05-20
CO7160042A2 (es) 2015-01-15
US20190153117A1 (en) 2019-05-23
MX356550B (es) 2018-06-01
CN104394879A (zh) 2015-03-04
US20170145107A1 (en) 2017-05-25
EP2832363A4 (en) 2016-03-23
BR112014024192A2 (pt) 2017-07-25
CN110317259A (zh) 2019-10-11
ES2694679T3 (es) 2018-12-26
MX2014011597A (es) 2015-03-10
KR101930019B1 (ko) 2018-12-17
WO2013147509A1 (ko) 2013-10-03
EP2832363B1 (en) 2018-09-19
RU2650770C2 (ru) 2018-04-17
CA2871111A1 (en) 2013-10-03
JP2015519875A (ja) 2015-07-16
IN2014DN08778A (enExample) 2015-05-22
KR20140145583A (ko) 2014-12-23
EP2832363A1 (en) 2015-02-04
DK2832363T3 (en) 2019-01-07
PH12014502360A1 (en) 2015-01-12
JP6209206B2 (ja) 2017-10-04
US20150231220A1 (en) 2015-08-20
MY168077A (en) 2018-10-11

Similar Documents

Publication Publication Date Title
US12447208B2 (en) Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses
TWI793439B (zh) 抗ｃｄ７３抗體及其應用
KR102503084B1 (ko) 항-ctla4 및 항-pd-1 이작용성 항체, 이의 약제학적 조성물 및 이의 용도
AU2011324870B2 (en) pan-HER antibody composition
JP6432121B2 (ja) Ｐｄｌ−１抗体、その医薬組成物及びその使用
US10221246B2 (en) Pan-HER antibody composition
KR101477762B1 (ko) 특이성 결합 단백질 및 용도
CN104098698A (zh) 一种抗cd3抗体及其制法和应用
US20190153117A1 (en) Epitopes of epidermal growth factor receptor surface antigen and use thereof
CN109879966B (zh) 基于鼠源cd19抗体的人源化设计及表达验证
CN109651509B (zh) 抗cd20的人源化单抗及其制剂
WO2024051223A1 (zh) 药物组合及用途
CN109593134B (zh) 抗cd20的人源化单克隆抗体及其制剂
HK40013803A (en) Epitopes of epidermal growth factor receptor surface antigen and use thereof
JP2022512724A (ja) 抗ｃｄ１３７抗体およびその使用
CN116635406B (zh) 一种包括抗间皮素scFv的嵌合抗原受体及其用途
CN113336847B (zh) 一种抗pd-1抗体

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180227

EEER Examination request

Effective date: 20180227